Table 1.
Therapy and outcome
| All patients (N = 88) | mo CEBPA (N = 43) | bi CEBPA (N = 45) | P | ||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Number of induction cycles | |||||||
| 1 | 29 | 33 | 16 | 37 | 13 | 30 | 0.41 |
| 2 | 59 | 67 | 27 | 63 | 32 | 71 | |
| Induction therapy regimen | 0.48 | ||||||
| In study | 76 | 86 | 36 | 84 | 40 | 89 | |
| In analogy to study | 12 | 14 | 7 | 16 | 5 | 11 | |
| Allogeneic SCT | 19 | 22 | 10 | 23 | 9 | 20 | 0.75 |
| in 1.CR | 7 | 8 | 3 | 7 | 4 | 9 | |
| Primary refractory | 4 | 5 | 3 | 7 | 1 | 2 | |
| At relapse | 8 | 9 | 4 | 9 | 4 | 9 | |
| Early death until day 30 | 4 | 5 | 3 | 7 | 1 | 2 | 0.28 |
| Early death until day 60 | 7 | 8 | 4 | 9 | 3 | 7 | 0.65 |
| CR/CRi* | 67 | 76 | 30 | 70 | 37 | 82 | 0.17 |
| Median OS, 95% CI, years | 3.0 (0.9-5.2) | 1.7 (0.7-2.7) | 9.6 (NA) | 0.008 | |||
| Median RFS, 95% CI, years | 2.3 (1.0-3.7) | 1.5 (0.4-2.5) | 9.4 (NA) | 0.021 | |||
*62 patients have achieved a CR; 5 patients have achieved a CRi;
Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CR complete remission, CRi CR with incomplete revovery, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, N number, NA not applicable, SCT stem cell transplantation.